Skip to main content
. 2022 Mar 28;14:1267–1281. doi: 10.2147/CMAR.S351383

Table 1.

Clinical Characteristics of the Studied Groups

Characteristics Flow Cytometry BMMCs qRT-PCR CD138+ PCs qRT-PCR BMMCs
Number of patients 98 30 38
Age, years
 Median 65 69 65
 Range 38–85 50–82 42–82
Gender, n (%)
 Female 50 (51.02) 21 (70.0) 11 (28.95)
 Male 48 (48.98) 9 (30.0) 27 (71.05)
International staging system (ISS), n (%)
 I 27 (27.56) 4 (13.33) 10 (26.32)
 II 30 (30.61) 13 (43.33) 14 (36.84)
 III 35 (35.71) 11 (36.67) 12 (31.58)
 Not available 6 (6.12) 2 (6.67) 2 (5.26)
Monoclonal protein type, n (%)
 IgG 60 (61.22) 17 (56.66)
8 (26.67)
5 (16.67)
23 (60.53)
13 (34.21)
2 (5.26)
 IgA 21 (21.43)
 Light chain 12 (12.24)
 Not available 5 (5.11)
Monoclonal protein concentration, n (%)*
 < 3 g/dl 43 (43.88) 13 (43.33) 19 (50.0)
 ≥ 3 g/dl 36 (36.73) 10 (33.34) 17 (44.74)
 Not available 19 (19.39) 7 (23.33) 2 (5.26)
Plasma cell (%)
 Median 25 37 18
 Range 10–84 10–84 10–80
Hemoglobin, n (%)
 < 10 g/dl 32 (32.65) 14 (46.67)
16 (53.33)
10 (26.32)
28 (73.68)
 ≥ 10 g/dl 62 (63.27)
 Not available 4 (4.08)
Serum creatinine, n (%)
 < 2 mg/dl 81 (82.65) 25 (83.33)
5 (16.67)
30 (78.95)
8 (21.05)
 ≥2 mg/dl 14 (14.29)
 Not available 3 (3.06)
Serum calcium, n (%)
 < 2.55 mmol/l 73 (74.49) 23 (76.67) 27 (71.05)
 ≥ 2.55 mmol/l 17 (17.35) 6 (20.0) 6 (15.79)
 Not available 8 (8.16) 1 (3.33) 5 (13.16)
Lactate dehydrogenase, n (%)
 Normal 63 (64.29) 20 (66.67) 24 (63.16)
 High 4 (4.08) 3 (10.00) 2 (5.26)
 Not available 31 (31.63) 7 (23.33) 12 (31.58)
High risk cytogenetics, n (%)**
 Yes 17 (17.35) 3 (10.0) 8 (21.05)
 No 39 (39.80) 7 (23.33) 16 (42.11)
 Not available 42 (42.85) 20 (66.67) 14 (36.84)

Notes: *Intact immunoglobulin MM; **del17p, t(4;14) or t(14;16).

Abbreviations: BMMCs, bone marrow mononuclear cells; PCs, plasma cells; qRT-PCR, quantitative reverse transcriptase-polymerase chain reaction.